Sui-Hong Chen

Learn More
INTRODUCTION In the past several decades, declining incidences of nasopharyngeal carcinoma (NPC) have been observed in Chinese populations in Hong Kong, Taiwan, Los Angeles, and Singapore. A previous study indicated that the incidence of NPC in Sihui County, South China remained stable until 2002, but whether age, diagnosis period, and birth cohort affect(More)
BACKGROUND Whether or not hepatitis B virus (HBV) infection plays a role in the development of nasopharyngeal carcinoma (NPC) is largely unknown. Our study aimed to assess the association between HBV infection and the risk of NPC in Southern China. METHODS We conducted a case-control study including 711 NPC cases and two groups of controls. The first(More)
BACKGROUND Serum immunoglobulin A antibodies against Epstein-Barr virus (EBV), viral capsid antigen (VCA-IgA) and early antigen (EA-IgA), are used to screen for nasopharyngeal carcinoma (NPC) in endemic areas. However, their routine use has been questioned because of a lack of specificity. This study aimed to determine the distributions of different(More)
OBJECTIVE Seven recombinant viral capsid antigen-IgA (VCA-IgA) ELISA kits are widely used in China, but their diagnostic effects have not been evaluated. In this study, we evaluated whether the diagnostic effects of these kits are similar to those of the standard kit (EUROIMMUN, Lübeck, Germany). METHODS A diagnostic case-control trial was conducted with(More)
OBJECTIVE To compare clinical characteristics between familial nasopharyngeal carcinomas (NPCs) and sporadic NPCs in Guangdong province, China, a high-risk area. METHODS Between 1991 and 2001, 993 NPC patients treated at the Cancer Center of Sun Yat-Sen University in Guangdong were randomly selected as probands. Information about NPC among the probands'(More)
Nasopharyngeal carcinoma (NPC) is a rare disease in the Western world, but it is endemic in certain parts of Southeast Asia and China. During the last decades, the outcome of the treatment has improved considerably. Concurrent chemo-radiation has become the treatment of choice in advanced NPC. Five years survival figures of 80-90 % for T1-T2 and 60-80 % for(More)
  • 1